- Home
- SVRA vs GERN Comparison
SVRA vs GERN Comparison
Compare SVRA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2009 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SVRA | GERN |
|---|---|---|
| Price | $4.52 | $1.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $11.06 | $4.25 |
| AVG Volume (30 Days) | 2.6M | ★ 6.0M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | N/A | $28.49 |
| Revenue Next Year | $4,406.08 | $44.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.86 | $1.04 |
| 52 Week High | $7.01 | $2.01 |
Technical Indicators
Market Signals| Indicator | SVRA | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 34.57 |
| Support Level | N/A | $1.08 |
| Resistance Level | $5.53 | $1.26 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 7.38 | 3.57 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.